Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary ...

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

(Reuters) -The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

With antibiotic-resistant gonorrhea on the rise, the vaccine could provide a way to prevent the disease from spreading.

Stocks from pharmaceutical companies and healthcare spaces dominated analysts' choices for Thursday's trading session.

Turning thet tide against tuberculosis . As the world's deadliest infectious disease surges, GSK and partners are pioneering ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...